Compare · IPEX vs NVO
IPEX vs NVO
Side-by-side comparison of Inflection Point Acquisition Corp. V (IPEX) and Novo Nordisk A/S (NVO): market cap, price performance, sector, and recent activity on the wire.
Summary
- Both IPEX and NVO operate in Biotechnology: Pharmaceutical Preparations (Health Care), so they compete in similar markets.
- NVO carries a market cap of $215.46B.
- Over the past year, IPEX is up 4.8% and NVO is down 14.7% - IPEX leads by 19.6 points.
- Both names hit the wire about 9 times in the past 4 weeks.
- NVO has more recent analyst coverage (25 ratings vs 0 for IPEX).
- Company
- Inflection Point Acquisition Corp. V
- Novo Nordisk A/S
- Price
- $10.62+0.57%
- $47.15-3.07%
- Market cap
- -
- $215.46B
- 1M return
- +0.66%
- -7.41%
- 1Y return
- +4.84%
- -14.73%
- Industry
- Biotechnology: Pharmaceutical Preparations
- Biotechnology: Pharmaceutical Preparations
- Exchange
- NASDAQ
- NYSE
- IPO
- 2025
- News (4w)
- 9
- 9
- Recent ratings
- 0
- 25
Novo Nordisk A/S
Novo Nordisk A/S, a healthcare company, engages in the research, development, manufacture, and marketing of pharmaceutical products worldwide. It operates in two segments, Diabetes and Obesity care, and Biopharm. The Diabetes and Obesity care segment provides products in the areas of insulins, GLP-1 and related delivery systems, oral antidiabetic products, obesity, and other chronic diseases. The Biopharmaceuticals segment offers products in the areas of haemophilia, growth disorders, and hormone replacement therapy. The company collaboration agreements with Lund University to develop treatment for Parkinson's diseases; and bluebird bio, Inc. to develop genome editing treatments for children and adult patients. Novo Nordisk A/S also has a research collaboration with Lumen Bioscience, Inc. to explore strategies for delivering oral biologics for cardiometabolic disease. The company was founded in 1923 and is headquartered in Bagsvaerd, Denmark.
Latest IPEX
- SEC Form 10-Q filed by Inflection Point Acquisition Corp. V
- A1R water Debuts as Publicly Traded Company to Build Leading CPG Brand in Atmospheric Water
- SEC Form SCHEDULE 13G filed by Inflection Point Acquisition Corp. V
- Inflection Point Acquisition Corp. V filed SEC Form 8-K: Amendments to Articles of Incorporation or Bylaws; Change in Fiscal Year, Submission of Matters to a Vote of Security Holders, Other Events, Financial Statements and Exhibits
- SEC Form SCHEDULE 13G filed by Inflection Point Acquisition Corp. V
- Inflection Point Acquisition Corp. V filed SEC Form 8-K: Regulation FD Disclosure, Financial Statements and Exhibits
- SEC Form 425 filed by Inflection Point Acquisition Corp. V
- SEC Form DEFA14A filed by Inflection Point Acquisition Corp. V
- Inflection Point Acquisition Corp. V and GOWell Energy Technology Announce Effectiveness of Registration Statement for Proposed Business Combination
- SEC Form DEF 14A filed by Inflection Point Acquisition Corp. V
Latest NVO
- SEC Form 6-K filed by Novo Nordisk A/S
- A New Category Is Forming in Medical Aesthetics. Independent Research Has Started Sizing It.
- SEC Form 6-K filed by Novo Nordisk A/S
- Novo Nordisk A/S downgraded by Berenberg
- SEC Form 6-K filed by Novo Nordisk A/S
- SEC Form 6-K filed by Novo Nordisk A/S
- SEC Form 6-K filed by Novo Nordisk A/S
- SEC Form 6-K filed by Novo Nordisk A/S
- SEC Form 6-K filed by Novo Nordisk A/S
- SEC Form 6-K filed by Novo Nordisk A/S